INmune Bio Inc. Announces 2025 Results and Provides Business Update...

INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, Ma...

INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach...

INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar...

INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB...

INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Ear...

INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB...

INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Init...